References

[1] Caminati A, Lonati C, Cassandro R, et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue [J]. European Respiratory Review: An Official Journal of the European Respiratory Society, 2019, 28(153). 

[2] Zeltz C, Primac I, Erusappan P, et al. Cancer-associated fibroblasts in desmoplastic tumors: Emerging role of integrins [J]. Semin Cancer Biol., 2020, 62: 166-81.

[3] Velagacherla V, Mehta C H, Nayak Y, et al. Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis [J]. Life Sci., 2022, 291: 120283.

[4] Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology [J]. The European Respiratory Journal, 2010, 35(3): 496-504.

[5] Kinoshita T, Goto T. Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review [J]. International Journal of Molecular Sciences, 2019, 20(6). 

[6] Otandault A, Anker P, Al Amir Dache Z, et al. Recent advances in circulating nucleic acids in oncology [J]. Ann Oncol., 2019, 30(3): 374-84.

[7] Totland M Z, Rasmussen N L, Knudsen L M, et al. Regulation of gap junction intercellular communication by connexin ubiquitination: physiological and pathophysiological implications [J]. Cellular and Molecular Life Sciences: CMLS, 2020, 77(4): 573-91.

[8] Chen Q, Boire A, Jin X, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer [J]. Nature, 2016, 533(7604): 493-8.

[9] Hu L, Ding M, He W. Emerging Therapeutic Strategies for Attenuating Tubular EMT and Kidney Fibrosis by Targeting Wnt/beta-Catenin Signaling [J]. Frontiers in Pharmacology, 2021, 12: 830340.

[10] Shaikh T B, Kuncha M, Andugulapati S B, et al. Dehydrozingerone alleviates pulmonary fibrosis via inhibition of inflammation and epithelial-mesenchymal transition by regulating the Wnt/beta-catenin pathway [J]. Eur J Pharmacol., 2023, 953: 175820.

[11] Ballester B, Milara J, Cortijo J. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets [J]. International Journal of Molecular Sciences, 2019, 20(3). 

[12] Chanda D, Otoupalova E, Smith S R, et al. Developmental pathways in the pathogenesis of lung fibrosis [J]. Molecular Aspects of Medicine, 2019, 65: 56-69.

[13] Wei K, Nguyen H N, Brenner M B. Fibroblast pathology in inflammatory diseases [J]. J Clin Invest., 2021, 131(20) 

[14] Chen P Y, Wei W F, Wu H Z, et al. Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling [J]. Frontiers in Immunology, 2021, 12: 671595.

[15] Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts [J]. Nat Rev Drug Discov., 2019, 18(2): 99-115.

[16] Mahalanobish S, Saha S, Dutta S, et al. Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis [J]. Pharmacol Res., 2020, 152: 104591.

[17] Li H X, Zheng J H, Fan H X, et al. Expression of alphavbeta6 integrin and collagen fibre in oral squamous cell carcinoma: association with clinical outcomes and prognostic implications [J]. J Oral Pathol Med., 2013, 42(7): 547-56.

[18] Ying H, Fang M, Hang Q Q, et al. Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-beta1/Smad3 pathway [J]. J Cell Mol Med., 2021, 25(18): 8662-75.

[19] Kinoshita T, Kudo-Saito C, Muramatsu R, et al. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma [J]. European Journal of Cancer (Oxford, England: 1990), 2017, 86: 15-27.

[20] Hegde S, Leader A M, Merad M. MDSC: Markers, development, states, and unaddressed complexity [J]. Immunity, 2021, 54(5): 875-84.

[21] Fernandez I E, Greiffo F R, Frankenberger M, et al. Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis [J]. The European Respiratory Journal, 2016, 48(4): 1171-83.